Icon

CYMBALTA (nda021427)- (EQ 20MG BASE,EQ 30MG BASE,EQ 60MG BASE)

DULOXETINE HYDROCHLORIDE LILLY
EQ 20MG BASE,EQ 30MG BASE,EQ 60MG BASE
Yes No
2020-Mar-10 Expired
None None
None No
CYMBALTA® is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: • Major depressive disorder (MDD) in adults • Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older • Diabetic peripheral neuropathic pain (DPNP) in adults • Fibromyalgia (FM) in adults and pediatric patients 13 years of age and older • Chronic musculoskeletal pain in adults.
21 3 18
Total Other Developers 29
Drugs with Suitability Yes
EQ 20MG BASE ** ** - - 11
EQ 30MG BASE ** ** Up - 10
EQ 60MG BASE ** ** Up - 10
NDA Sales Available Total Generic Sales Available
Yes 13
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** *** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** ******** ****** ******** ****** ******* *********** **** ** *-** & *-**, ***** ********** ******,, *****, *** ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** ***** ******** ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** *****-****** *******, *****, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** *** ******** ****** ******* ******* *** *********** ****-**, **.**'*.**,**,**,**,** ** **,***&***, ************** * & **.** *,*,****,**,**,**,**&**, ************ *, *********** ******, **********, ****** ******* ******, ***** (***) ***
****** ******** ******** ********** ******* *********** **-**/*-***/*, ********** ********* ************* (****),, *****, *********** ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ************ **** ************** ******, *.*. *********** ***** ** **** *****, **-**, ***********, *****, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***/*, ***, ***/*, ***/* & ***/* ******* ****** ***** *****, *******, *****, ***** & *** ******, ***** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ****** ****** *** ****** ****** ******* *********** **** **. *-*** /* ***** *** - **** **, *******, ******* ******, ***** (***) ***
****** ****** ****** *** ****** ****** ******* *********** *-*\*\*, **** ****, *******, *********** *************, *********** ******, ***** (***) ***
****** ******* ****** ***** *** *********, ***. *** *********** **.**, **. ***, ***** *. **., ***** ****., ******* ****, *****, ****** (***) ***
****** ******* ****** ***** ******* ****** ************** **.,***. *********** **. ** ***** ****, **** ********, *******, ******** ******, ***** (***) ***
****** ***** *** *** ********** ** **, *** *** ******* **** *********** *** ******* ******* *****, *******, ******** (**) *****, ****** ****** (***) ***
****** ******* ********* ************ ******** ** *********** *, ********** ****** ***., ********, ****, ******** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.